Articles tagged with Chemotherapy
A new study found that 18F-FDG PET scans accurately predict lymphoma treatment outcomes, especially after one cycle of chemotherapy. The test's sensitivity was higher after the first cycle, making it a better predictor of outcome and response to therapy.
Patients with ER-negative tumors who received chemotherapy had a 15% increase in disease-free survival and 89% overall survival rate. In contrast, those with ER-positive tumors did not show additional survival benefits from chemotherapy. The study suggests tailoring cancer treatments to patient characteristics.
A randomized trial found that adding chemotherapy to tamoxifen significantly increases disease-free and overall survival rates for postmenopausal women with lymph node-negative, ER-negative breast cancer. In contrast, no survival benefit was observed for those with ER-positive tumors.
A study published in Journal of Clinical Oncology found that self-taught stress management techniques, such as progressive muscle relaxation and guided imagery, can significantly improve the quality of life for cancer patients undergoing chemotherapy. These techniques were more effective than traditional methods when learned independen...
A study identified three gene expression patterns correlated with survival after chemotherapy, which outperformed the International Prognostic Index. The patterns revealed aspects of tumor biology affecting treatment response, including immune system involvement and tumor cell division.
Kytril was found to be significantly more effective than dolasetron in controlling acute chemotherapy-induced nausea and vomiting. The study, led by Dr. Marianne Tan, showed that 69.2% of patients treated with Kytril experienced total control of nausea and vomiting, compared to 23.1% for dolasetron.
Researchers analyzed gene expression profiles from thousands of lymphoma biopsy samples to identify predictive genes that can predict patient response to treatment and survival rates. The study found that a formula created from 17 key genes could accurately classify patients into four groups with varying five-year survival rates.
A study found that the GSTP1 polymorphism was associated with increased survival in patients with advanced colorectal cancer who received platinum-based chemotherapy. Meanwhile, research on human herpesvirus-8 suggested that the K1 gene may play a role in malignant transformation.
A new clinical trial at NCCAM investigates the effectiveness of electroacupuncture in managing delayed chemotherapy-induced nausea, which often proves difficult to treat with medications. The study aims to provide an alternative approach to alleviate this condition and its associated side effects, such as stress.
Researchers developed a test to predict which patients with locally advanced breast cancer are likely to respond to chemotherapy, and found it was accurate 100% of the time. The test used radiotracer uptake and washout rates to identify patients who would benefit from specific drugs to boost their response.
BP7787 shows impressive safety profile and high tumor response rate, indicating potential as a preventive measure for chemotherapy side effects. The Phase 1 clinical trial demonstrated no severe nerve damage and partial tumor remission in nearly all patients treated with BNP7787
Researchers found that elderly patients with lymph node involvement in colon cancer experienced a 30% reduction in mortality at five years after diagnosis with both chemotherapy and surgery. This contradicts the common assumption that age is a deterrent for these treatments, allowing doctors and patients to make more informed decisions.
A study found that 40% of patients experienced improved lung cancer symptoms after taking the experimental pill ZD 1839, leading to a longer survival and better quality of life. The pill, which targets the epidermal growth factor receptor, was found to be well-tolerated with minimal side effects.
Researchers have developed a new breast cancer therapy that combines heat therapy, chemotherapy, and fat liposomes to deliver drugs directly to tumors. The treatment has shown promising results, destroying tumors and saving patients' breasts from surgical removal.
Researchers evaluated 407 patients who had surgery to remove their cancer and were at high risk for recurrence. The study found no significant difference between radiation alone and chemotherapy plus radiation in reducing cancer recurrence or improving overall survival rates.
A recent study by the Southwest Oncology Group found that long-term treatment with prednisone after initial chemotherapy response significantly prolonged patient survival and delayed disease progression in those with multiple myeloma. Patients receiving higher doses of prednisone lived up to 37 months longer than those on lower doses.
Scientists have created a novel approach to deliver medication through implanted medical devices using electrical currents, which could lead to improved chemotherapy treatments and enhanced patient quality of life.
Researchers found that elevated troponin I levels may predict future heart failure in cancer patients, even if the heart appears to be functioning normally. ACE inhibitors have shown promise in restoring cardiac function and preventing cardiotoxicity in breast cancer patients treated with anthracyclines.
A new study found that neoadjuvant therapy can significantly improve long-term survival rates for women with locally advanced breast cancer. The treatment allows for less drastic and breast-sparing surgery, increasing the chances of successful tumor downstaging and improved outcomes.
Researchers found that mitoxantrone induction therapy significantly reduced disease activity in MS patients, with a 76% relapse-free rate at one year and 64% at four years. The annual relapse rate decreased by nearly 90% following treatment.
A survey by Johns Hopkins researchers estimates probable environmental concentrations (PECs) of the top 200 drugs, suggesting potential sublethal effects on aquatic organisms. The study suggests that certain classes of compounds, such as antimicrobials and anticancer drugs, may be found at high concentrations.
Researchers at Thomas Jefferson University found that low doses of paclitaxel and docetaxel inhibit the growth of endothelial cells, leading to smaller tumors. The study suggests that oral versions of these drugs could be effective in treating cancer with chronic, low dose concentrations.
Researchers have discovered four biochemical markers that can predict a woman's likelihood of developing metastatic disease in node-negative breast cancer. These markers, including p53, E-cadherin, and nm23H1, were found to be significant predictors of outcome, allowing for more accurate identification of patients at risk. This breakth...
A touch screen questionnaire found that breast cancer patients experience similar levels of adverse side-effects from chemotherapy, regardless of age. The study also revealed that older women are more susceptible to fatigue, anorexia, weight loss, and mouth ulcers during treatment.
Systematic review and meta-analysis of 12 randomised trials shows a 6% increase in one-year survival for patients receiving chemotherapy with radiotherapy compared to those receiving radiotherapy alone. Patients also experience a two-month improvement in average survival time.
A new study has validated data on 73 patients with lymph-node negative breast cancer under 55, predicting disease-free survival with 90% certainty. This could lead to a 30-40% reduction in chemotherapy use for these patients, resolving the dilemma of overtreatment.
A recent study by Fred Hutchinson Cancer Research Center found that marrow transplantation using an unrelated donor can be as successful as transplants with related donors for treatment of children with acute leukemia, particularly those under age 10. The study showed a 70% leukemia-free survival rate for patients in their first remiss...
A study by physicians at 10 hospitals in the US and Canada found that continuous doxorubicin infusion for children with acute lymphoblastic leukemia does not prevent heart damage, contrary to previous assumptions. The treatment resulted in increased hospitalizations and higher medical costs.
A study by Prof. Kerem and Asaf Hellman found that chemotherapy drugs can cause chromosomes to break at specific regions, known as fragile sites, potentially leading to cancer growth. The research creates a better understanding of how cancer drugs work, paving the way for more effective treatments.
Researchers warn that patients with testicular cancer are living long enough to suffer from life-threatening side effects, including cardiovascular disease. Studies found that nearly a third had abnormal heart function, while over 80% had raised cholesterol levels.
A new combination of MabThera and standard chemotherapy has shown a significant increase in overall survival rate and complete remission rates in patients with aggressive non-Hodgkin's lymphoma. This treatment offers hope for improved outcomes in this increasingly common form of blood cancer.
A new global survey found that 91% of physicians prescribe MabThera for NHL, with 62% citing proven efficacy in combination with chemotherapy. Non-Hodgkin's Lymphoma affects 1.5 million people worldwide, with Roche's MabThera showing improved survival rates when combined with conventional chemotherapy.
Researchers found that the MabThera plus CHOP combination significantly improves overall survival for patients with aggressive non-Hodgkin's lymphoma, with a 70% survival rate after 26 months. The treatment is also effective in treating indolent NHL, with up to 55% of patients remaining in remission at four years.
Researchers at Massachusetts General Hospital found that a certain chemotherapy drug combination can increase the risk of lung inflammation in breast cancer patients. The study suggests doctors use extra caution when administering radiation therapy with paclitaxel, as it may lead to radiation pneumonitis in up to 14.6% of patients.
Researchers have identified a compound in myrrh that kills cancer cells in the laboratory, showing promise for breast and prostate cancer prevention and treatment. The compound, which inactivates a specific protein overproduced by cancer cells, is estimated to be 100 times less potent than conventional chemotherapy drugs.
Researchers at USC/Norris Comprehensive Cancer Center developed a test that analyzes tumor tissue to predict response to oxaliplatin and 5-FU chemotherapy. Patients with low ERCC1 and TS expression survived longer than those with high levels, indicating the potential for more effective treatment customization.
A new treatment regimen combining chemotherapy and radiation therapy significantly improved failure-free survival rates for patients with early-stage Hodgkin's disease. The study also found that staging laparotomy could be avoided, leading to better patient outcomes.
Researchers found that small doses of suramin enhanced chemotherapy effectiveness in treating advanced stage IIIB/IV lung cancer. The tumors halved in seven patients and didn't progress in eight, showing a potential treatment option for patients with metastatic lung cancer.
Researchers at Ohio State University are studying a new treatment that blocks the production of Bcl-2, a protein overexpressed in many cancers, and found nearly half of 20 patients responding favorably. The treatment showed safety and induced disease remission in some patients.
A University of Houston scientist has developed a DNA biochip that can screen for thousands of genetic mutations and diseases with one simple lab test. The device uses micromirrors to project light patterns onto the chip, triggering chemical reactions that build up individual DNA strands.
The HERA (HERceptin Adjuvant) Study aims to determine if earlier use of Herceptin increases disease-free survival for women with early breast cancer. The trial will recruit over 3000 patients across 600 trial sites globally.
The TALENT trial assesses Tarceva's value in NSCLC treatment, showing promising anti-tumor activity. Additionally, a Phase Ib study evaluates Tarceva's feasibility in combination with chemotherapy for advanced breast cancer.
Researchers have identified Candidatus Endobugula sertula bacteria in Bugula neritina as the likely source of the anti-cancer compound Bryostatin 1. The study provides a new experimental system to unlock the potential of bryostatin drugs.
A new study published in New England Journal of Medicine found that age alone should not determine whether an older patient is offered chemotherapy after surgery for treatment of stage II and III colon cancer. The study showed a significant reduction in death risk and improved survival rates among patients over 70 with the disease.
Researchers propose a novel strategy for anti-angiogenic treatment by normalizing tumor blood vessels, improving drug delivery and reducing side effects. Clinical trials are planned to test the efficacy of this approach.
Recruitment to breast cancer chemotherapy trials for women at high risk of the disease remains a concern in the UK. A recent study found that only 10% of eligible women opted for these trials, highlighting the need for increased recruitment efforts.
Researchers at Scripps Research Institute have solved the first high-resolution structure of a membrane transporter, which can help design new drugs against antibiotic-resistant bacteria and certain cancer cells. The breakthrough could lead to increased efficacy of chemotherapy agents.
A systematic review of randomised trials found that women treated with combined chemotherapy and radiotherapy had an increased survival rate of 12% and reduced local and distant disease recurrence by around 40%. However, toxic side-effects were more common.
Research studies found that low MBL concentrations are associated with prolonged fever and infection in cancer patients undergoing chemotherapy. MBL infusions may represent a new therapeutic approach to reduce illness and death for these patients.
Jean M.J. Frechet, a renowned Berkeley chemist, has been honored with the 2001 Arthur C. Cope Scholar Award for his groundbreaking research on dendrimers, complex organic compounds with various applications, including drug delivery to tumors and light-harvesting antennae.
A recent trial found that WHO short-course chemotherapy was as effective as traditional Russian treatments in curing patients with tuberculosis. However, the results highlight the challenges of implementing changes in a healthcare system with entrenched cultural and structural barriers.
A clinical trial found that marimastat produced comparable one-year survival rates to chemotherapy drug gemcitabine in patients with localized pancreatic cancer. Fewer toxic side effects were reported in patients taking marimastat compared to gemcitabine.
A statistical analysis of 47 randomized trials involving 18,000 women found that chemotherapy improves survival time adjusted for quality of life for both younger and older women. Younger women treated with chemotherapy gained an average of 10.3 months of relapse-free survival within 10 years.
Researchers found that 71% of women experienced ovarian function loss and rapid bone loss after six months of chemotherapy, leading to significant bone loss by the end of one year. The study suggests that earlier intervention with calcium, vitamin D, weight-bearing exercise, and counseling may help prevent bone loss in these patients.
A new study published in Psycho-Oncology found that people with advanced cancer are more willing to consider toxic chemotherapy regimens, even if they offer only minimal benefits. Cancer patients generally accepted both milder and riskier treatments, unlike healthy individuals and healthcare professionals.
Researchers found that patients with the lowest activity of a key folate-metabolizing enzyme suffered the highest degree of toxicity and treatment complications. Patients with the MTHFR variant had less than half the rate of folate-enzyme activity, resulting in increased oral mucositis symptoms and slower platelet recovery.
A heat-sensitive liposome has been shown to triple the amount of an anti-cancer drug delivered to tumors in mice compared to other liposome-based methods. The liposome releases its cargo rapidly and effectively, increasing the functional concentration of the drug in the tumor.
A study at the American Society of Hematology Meeting found that patients with acute myeloid leukemia who achieve remission with Mylotarg have prolonged disease-free survival following stem cell transplantation. Researchers also observed fewer complications from bone marrow transplants compared to traditional treatment.
A Phase III study found significant improvements in overall survival, disease-free status, and complete remission rates for patients with aggressive non-Hodgkin's lymphoma treated with MabThera and CHOP chemotherapy. Survival at 1-year was 83% for the rituximab combination therapy group compared to 68% for those receiving CHOP alone.
A new study in the Archives of Disease in Childhood found a low overall drug error rate in a pediatric teaching hospital in the UK, with one mistake for every 662 admissions. However, a significant proportion of parents were not informed about medication errors, with 48% of cases going unreported.